Fig. 3
From: New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells
CasAnalyzer results on editing efficiency on COL4A5 podocyte-lineage cells. CasAnalzyer Tool operating on the CRISPR/Cas9 treated sample and control has reported a HDR of 58.8% in patients’ mutated podocyte-lineage cells. IGV Visualization Software for the variant shows how there is a substantial loss of heterozygosity with the restoration of the wild-type base, confirming the functionality of the system
